Skip To Main Content

Actualización normativa

En un entorno en constante cambio como el sistema de salud, es fundamental mantenerse al día con las nuevas normativas que afectan tanto a profesionales como a pacientes. En este espacio encontrará las leyes, decretos, resoluciones y acuerdos relacionados con el sistema de salud dinámico y en evolución.

También encontrará resúmenes, análisis y todo lo relacionado con la más reciente normatividad, para comprender el posible impacto de los cambios hacia los diferentes actores del sistema.

Ordenar por
BR1DGE Symposium at EASD 2024

BR1DGE Symposium at EASD 2024

At the BR1DGE symposium at EASD 2024, leading experts shared new insights on early-stage (Stage 1 and 2) autoimmune type 1 diabetes (T1D), emphasizing the importance of screening for islet antibodies (IAbs) together with monitoring and education. Early type 1 diabetes identification can help to prepare people for a life with T1D.

This article is intended to be a summary only. Additional topics were covered in the live symposium in line with the applicable regulations but are not included on the BR1DGE platform.

Impacto de Rinitis Alérgica y Urticaria en Calidad de Vida

Impacto de Rinitis Alérgica y Urticaria en Calidad de Vida

Advances in the biology of chronic GVHD

Advances in the biology of chronic GVHD

Updated European Society of Blood and Marrow Transplantation consensus recommendations for GVHD prophylaxis and management in hematological malignancies after stem-cell transplantation

Updated European Society of Blood and Marrow Transplantation consensus recommendations for GVHD prophylaxis and management in hematological malignancies after stem-cell transplantation

Clinical outcomes of cGvHD following allogeneic HSCT: A Swedish population-based real-world registry study

Clinical outcomes of cGvHD following allogeneic HSCT: A Swedish population-based real-world registry study

Clinical outcomes of cGvHD following allogeneic HSCT: A Swedish population-based real-world registry study

Clinical outcomes of cGvHD following allogeneic HSCT: A Swedish population-based real-world registry study

Updated European Society of Blood and Marrow Transplantation consensus recommendations for GVHD prophylaxis and management in hematological malignancies after stem-cell transplantation

Updated European Society of Blood and Marrow Transplantation consensus recommendations for GVHD prophylaxis and management in hematological malignancies after stem-cell transplantation

Advances in the biology of chronic GVHD

Advances in the biology of chronic GVHD

Updated European Society of Blood and Marrow Transplantation consensus recommendations for GVHD prophylaxis and management in hematological malignancies after stem-cell transplantation

Updated European Society of Blood and Marrow Transplantation consensus recommendations for GVHD prophylaxis and management in hematological malignancies after stem-cell transplantation

Advances in the biology of chronic GVHD

Advances in the biology of chronic GVHD

Clinical outcomes of cGvHD following allogeneic HSCT: A Swedish population-based real-world registry study

Clinical outcomes of cGvHD following allogeneic HSCT: A Swedish population-based real-world registry study

건강한 신생아 및 영아에서 RSV 관련 하기도 감염으로 인한 입원 예방에 있어 Nirsevimab의 효능과 안전성

건강한 신생아 및 영아에서 RSV 관련 하기도 감염으로 인한 입원 예방에 있어 Nirsevimab의 효능과 안전성

Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants
S.B. Drysdale, K. Cathie, F. Flamein, M. Knuf, A.M. Collins, H.C. Hill, F. Kaiser, R. Cohen, D. Pinquier, C.T. Felter, N.C. Vassilouthis, J. Jin, M. Bangert, K. Mari, R. Nteene, S. Wague, M. Roberts, P. Tissières, S. Royal, and S.N. Faust, for the MELODY Study Group. N Eng J Med. 2023; 389: 2425–2435.

Material diseñado por o para Sanofi Aventis de Colombia S.A., con fines educativos y dirigido a profesionales de la salud y personal administrativo del sector salud. Es estrictamente prohibido compartir este material con terceros.

Mayor información a disposición en el Departamento Médico:

En Colombia:

Sanofi-Aventis de Colombia S.A. Transversal 23 N° 97-73 - Edificio City Business. Piso 8. Bogotá D.C. Teléfono: 621 4400 - Fax: 744 4237

infomedica.colombia@sanofi.com

En Bolivia, Centro América y Caribe:

Sanofi-Aventis de Panamá S.A. Torre Evolution, piso 26, Calle 50 y Av. Aquilino de la Guardia Obarrio- Cuidad de Panamá, República de Panamá Telf.: (507) 382-9500. infomed.pac@sanofi.com

Sitio web: http://www.sanofi.com.pa/l/pa/sp/index.jsp

 

MAT-CO-2400825 V1.0 03/2024